FDA cautiously backs two abuse-deterrent opioids — 3 insights

The FDA approved Vantrela and Troxyca, two abuse-deterrent opioids, but also asked the medical community for better evaluations on abuse-deterrence, according to MedPage Today.

Here are three insights:

1. The Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety Risk Management Advisory Committee approved the two drugs.

2. The panel voted 14 to 3 on Vantrela, and 9 to 6 on Troxyca.

3. Vantrela is an abuse-deterrent formulation of extended-release hydrocodone. Troxyca is an abuse-deterrent formulation of extended-release oxycodone with naltrexone.

More articles on quality & infection control:
NY legislation exempts drugstores from some patient safety standards: 5 things to know
Top 10 states with the highest & lowest ASC patient burn rates
FDA eases paperwork burden for experimental drugs — 5 notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Patient Safety Tools & Resources Database

Featured Webinars

Featured Whitepapers